Crossmark

Comment on: “Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors”

Crossref DOI link: https://doi.org/10.1007/s10549-026-07946-0

Published Online: 2026-03-18

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Manikya, Sangameshwar https://orcid.org/0000-0002-9544-2463
Vadhithala, Varshini https://orcid.org/0009-0008-7536-5406
Kumar, Rajnish

Nainwal, Pankaj
License Information

Text and Data Mining valid from 2026-03-18

Version of Record valid from 2026-03-18
More Information

Article History

Received: 16 February 2026

Accepted: 11 March 2026

First Online: 18 March 2026

Declarations

:

: The authors declare no competing interests.

: Not required.

: Not applicable, as this study does not report a clinical trial.

: Not applicable.

: Not applicable, as no patient data were collected or analyzed in this study.

Document is current

Any future updates will be listed below